Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial.

被引：11
|
作者：
Cella, David [1 ]
Choueiri, Toni K. [2 ]
Blum, Steven, I [3 ]
Ejzykowicz, Flavia [3 ]
Hamilton, Melissa [3 ]
Zhang, Joshua [3 ]
Ivanescu, Cristina [4 ]
Motzer, Robert J. [5 ]
机构：
[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[2] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] IQVIA, Herikerbergweg, Netherlands
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.285
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
285
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
    Cella, David
    Motzer, Robert J.
    Suarez, Cristina
    Blum, Steven, I
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel F.
    Simsek, Burcin
    Zhang, Joshua
    Ivanescu, Cristina
    Apolo, Andrea B.
    Choueiri, Toni K.
    LANCET ONCOLOGY, 2022, 23 (02): : 292 - 303
  • [2] First-line nivolumab plus cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
    Porta, C. G.
    Burotto, M.
    Suarez Rodriguez, C.
    Bourlon, M. T.
    Hsieh, J.
    Shah, A. Y.
    Hamzaj, A.
    Bedke, J.
    Pook, D.
    Kessler, R.
    Tomita, Y.
    Drakaki, A.
    Zhang, J.
    Simsek, B.
    Schwab, G.
    Escudier, B.
    Motzer, R. J.
    Choueiri, T. K.
    Apolo, A. B.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S688 - S689
  • [3] Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
    Benjamin Duy Tran
    Jing Li
    Neang Ly
    Raffaella Faggioni
    Lorin Roskos
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 179 - 189
  • [4] Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
    Tran, Benjamin Duy
    Li, Jing
    Ly, Neang
    Faggioni, Raffaella
    Roskos, Lorin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (02) : 179 - 189
  • [5] Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
    Apolo, Andrea B.
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria Teresa
    Hsieh, James J.
    Basso, Umberto
    Shah, Amishi Yogesh
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos H.
    Gurney, Howard
    Kessler, Elizabeth R.
    Retz, Margitta
    George, Saby
    Escudier, Bernard
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
    Burotto, Mauricio
    Powles, Thomas
    Escudier, Bernard
    Apolo, Andrea B.
    Bourlon, Maria Teresa
    Shah, Amishi Yogesh
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos H.
    Richardet, Martin
    Gurney, Howard
    Kessler, Elizabeth R.
    Tomita, Yoshihiko
    Bedke, Jens
    George, Saby
    Scheffold, Christian
    Wang, Peter
    Fedorov, Viktor
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Powles, Thomas
    Burotto, Mauricio
    Apolo, Andrea B.
    Escudier, Bernard
    McDermott, David F.
    Braun, David A.
    Han, Celine
    Lee, George
    Dwivedi, Bhakti
    Li, Jun
    Gupta, Saurabh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [8] Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N plus C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).
    Shah, Amishi Yogesh
    Motzer, Robert J.
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Zhang, Joshua
    Scheffold, Christian
    Karumanchi, Sravan
    Linh Thuy Nguyen
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Bourlon, M. T.
    Zurawski, B.
    Oyervides Juarez, V. M.
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Barrios, C. H.
    Richardet, M.
    Pook, D.
    Tomita, Y.
    Escudier, B.
    Zhang, J.
    Simsek, B.
    Apolo, A. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1159 - S1159
  • [10] Nivolumab plus cabozantinib (N plus C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Pook, David
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria T.
    Hsieh, James J.
    Basso, Umberto
    Shah, Amishi Y.
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos
    Gurney, Howard
    Kessler, Elizabeth R.
    Retz, Margitta
    George, Saby
    Escudier, Bernard
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    Apolo, Andrea B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 131 - 131
12345